NCT03951831 2025-04-25
REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer
Columbia University
Phase 2 Active not recruiting
Clinical Trials
11 trialsNCT00587431 2023-11-07
Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT05557604 2022-09-28
STUNNIN
Regina Elena Cancer Institute
Phase 2 Recruiting
NCT00004635 2018-05-22
Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 3 Completed
NCT01431391 2017-05-30
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
Dendreon
Phase 2 Completed
NCT01642732 2017-05-30
Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 1 Terminated
NCT02749825 2016-04-25
Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer
Pharmatech
Phase 4 Terminated
NCT01603420 2016-03-14
External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer
Proton Collaborative Group
Phase 2/3 Terminated
NCT00630799 2010-09-09
Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients
GP-Pharm
Phase 3 Terminated
NCT00167648 2009-01-19
NE2
University of Washington
Phase 2 Completed
NCT00076531 2008-01-28
Clinical Trial for Prostate Cancer
Oakwood Laboratories, LLC
Phase 3 Completed